Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat

Open access

Abstract

Meditation and psychedelics have played key roles in humankind’s search for self-transcendence and personal change. However, neither their possible synergistic effects, nor related state and trait predictors have been experimentally studied. To elucidate these issues, we administered double-blind the model psychedelic drug psilocybin (315 μg/kg PO) or placebo to meditators (n = 39) during a 5-day mindfulness group retreat. Psilocybin increased meditation depth and incidence of positively experienced self-dissolution along the perception-hallucination continuum, without concomitant anxiety. Openness, optimism, and emotional reappraisal were predictors of the acute response. Compared with placebo, psilocybin enhanced post-intervention mindfulness and produced larger positive changes in psychosocial functioning at a 4-month follow-up, which were corroborated by external ratings, and associated with magnitude of acute self-dissolution experience. Meditation seems to enhance psilocybin’s positive effects while counteracting possible dysphoric responses. These findings highlight the interactions between non-pharmacological and pharmacological factors, and the role of emotion/attention regulation in shaping the experiential quality of psychedelic states, as well as the experience of selflessness as a modulator of behavior and attitudes. A better comprehension of mechanisms underlying most beneficial psychedelic experiences may guide therapeutic interventions across numerous mental conditions in the form of psychedelic-assisted applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-50612-3

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Levels of state mindfulness (Toronto Mindfulness Scale total score) and (B) meditation depth (Meditation Depth Questionnaire total score) over the course of the retreat. Data are means ± 1 SEM (standard error of the mean). The asterisk indicates a significant difference between psilocybin and placebo groups on day 4, when the drug was administered (*p < 0.01). Both state mindfulness and meditation depth increased between day 1 and day 5 (mindfulness, mean ± SEM: 29.61 ± 1.18 and 32.42 ± 1.36 on day 1 and day 5, respectively, p < 0.05; meditation depth, mean ± SEM: 63.0 ± 3.31 and 77.7 ± 3.74 on day 1 and day 5, respectively, p < 0.001). The p-values have been adjusted for multiple comparisons within this analysis.
Figure 1 (A) Levels of state mindfulness (Toronto Mindfulness Scale total score) and (B) meditation depth (Meditation Depth Questionnaire total score) over the course of the retreat. Data are means ± 1 SEM (standard error of the mean). The asterisk indicates a significant difference between psilocybin and placebo groups on day 4, when the drug was administered (*p < 0.01). Both state mindfulness and meditation depth increased between day 1 and day 5 (mindfulness, mean ± SEM: 29.61 ± 1.18 and 32.42 ± 1.36 on day 1 and day 5, respectively, p < 0.05; meditation depth, mean ± SEM: 63.0 ± 3.31 and 77.7 ± 3.74 on day 1 and day 5, respectively, p < 0.001). The p-values have been adjusted for multiple comparisons within this analysis.CC BY · PubMed Central
Figure 2 Trait mindfulness (Freiburg Mindfulness Inventory score) pre- and post-retreat. The score was significantly higher in the psilocybin group than in the placebo group on day 6, 2 days after psilocybin administration (*p < 0.001). When collapsed across the two groups (independent of drug treatment), trait mindfulness was significantly higher on day 6 (mean ± SEM: 46.2 ± 0.73) than on day 0 (mean ± SEM: 43.3 ± 0.70). The p-values have been adjusted for multiple comparisons within this analysis.
Figure 2 Trait mindfulness (Freiburg Mindfulness Inventory score) pre- and post-retreat. The score was significantly higher in the psilocybin group than in the placebo group on day 6, 2 days after psilocybin administration (*p < 0.001). When collapsed across the two groups (independent of drug treatment), trait mindfulness was significantly higher on day 6 (mean ± SEM: 46.2 ± 0.73) than on day 0 (mean ± SEM: 43.3 ± 0.70). The p-values have been adjusted for multiple comparisons within this analysis.CC BY · PubMed Central
Figure 3 Effects of psilocybin on the subscales of the Altered States of Consciousness Rating Scale (5D-ASC). Scores are expressed as percent of scale maximum. Error bars indicate ± 1 SEM (standard error of the mean). Asterisks indicate significant differences between psilocybin and placebo groups (***p < 0.0001, **p < 0.001, *p < 0.05). OB, Oceanic Boundlessness; AED, Anxious Ego Dissolution; VR, Visual Restructuralization. The p-values have been adjusted for multiple comparisons within this analysis.
Figure 3 Effects of psilocybin on the subscales of the Altered States of Consciousness Rating Scale (5D-ASC). Scores are expressed as percent of scale maximum. Error bars indicate ± 1 SEM (standard error of the mean). Asterisks indicate significant differences between psilocybin and placebo groups (***p < 0.0001, **p < 0.001, *p < 0.05). OB, Oceanic Boundlessness; AED, Anxious Ego Dissolution; VR, Visual Restructuralization. The p-values have been adjusted for multiple comparisons within this analysis.CC BY · PubMed Central
Figure 4 Effect of psilocybin on sub-dimensions of the M-scale. Error bars are ± 1 SEM (standard error of the mean). Asterisks indicate significant differences between psilocybin and placebo groups (**p < 0.001). The p-values have been adjusted for multiple comparisons within this analysis.
Figure 4 Effect of psilocybin on sub-dimensions of the M-scale. Error bars are ± 1 SEM (standard error of the mean). Asterisks indicate significant differences between psilocybin and placebo groups (**p < 0.001). The p-values have been adjusted for multiple comparisons within this analysis.CC BY · PubMed Central
Figure 5 (A) M-scale total score for lifetime experience versus acute drug experience for psilocybin and placebo groups. Error bars indicate ± 1 SEM (standard error of the mean). Asterisk indicates a significant difference between psilocybin and placebo groups (*p < 0.01). (B) M-scale total score for each participant. The a priori criterion of 60% of scale maximum for a “strong” mystical-type experience was met by 19 of 20 participants (95%) in the psilocybin group and 3 of 19 participants (15.8%) in the placebo group.
Figure 5 (A) M-scale total score for lifetime experience versus acute drug experience for psilocybin and placebo groups. Error bars indicate ± 1 SEM (standard error of the mean). Asterisk indicates a significant difference between psilocybin and placebo groups (*p < 0.01). (B) M-scale total score for each participant. The a priori criterion of 60% of scale maximum for a “strong” mystical-type experience was met by 19 of 20 participants (95%) in the psilocybin group and 3 of 19 participants (15.8%) in the placebo group.CC BY · PubMed Central
Figure 6 Comparison of subjective effects in participants from the psilocybin group (n = 19) with those in the placebo group (n = 3), who reached the a priori criteria for a “strong” mystical-type experience. Despite similar M-scale subdimensions (C), there were marked differences in various scale and subscale scores of altered states of consciousness (A,B), particularly in the domain of visual experiences.
Figure 6 Comparison of subjective effects in participants from the psilocybin group (n = 19) with those in the placebo group (n = 3), who reached the a priori criteria for a “strong” mystical-type experience. Despite similar M-scale subdimensions (C), there were marked differences in various scale and subscale scores of altered states of consciousness (A,B), particularly in the domain of visual experiences.CC BY · PubMed Central
Figure 7 Self-rated changes in attitude and behavior, evaluated using the Life Change Inventory, Revised, at a 4-month follow-up. Error bars indicate ± 1 SEM (standard error of the mean). Asterisks indicate significant differences between psilocybin and placebo groups (***p < 0.001, *p < 0.01, #p < 0.05–0.07). The p-values have been adjusted for multiple comparisons within this analysis.
Figure 7 Self-rated changes in attitude and behavior, evaluated using the Life Change Inventory, Revised, at a 4-month follow-up. Error bars indicate ± 1 SEM (standard error of the mean). Asterisks indicate significant differences between psilocybin and placebo groups (***p < 0.001, *p < 0.01, #p < 0.05–0.07). The p-values have been adjusted for multiple comparisons within this analysis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

10 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 95 references

Research works printed but not linked: 15

  1. Pahnke, W. N. Drugs & Mysticism: An Analysis of the Relationship between Psychedelic Drugs and Mystical Consciousness Divinity. Harvard University, Cambridge MA, 315 (1963).
  2. Hood, R. W., Hill, P. C. & Spilka, B. The psychology of religion: An empirical approach. (Guilford Press, 2009).
  3. Nichols, D. E. & Chemel, B. R. The neuropharmacology of religious experience: Hallucinogens and the experience of the divine. Where God and science meet: How brain and evolutionary studies alter our understanding of religion 3, 1–33 (2006).
  4. Piron, H. The meditation depth index (MEDI) and the meditation depth questionnaire (MEDEQ). Journal for Meditation and Meditation Research 1, 69–92 (2001).
  5. Hölzel, B. K. & U. O., Relationship between mediation depth, absorption, mediation practice, and mindfullness: A laten variable approach. The Journal of Transpersonal Psychology 38, 20 (2006).
  6. Studerus, E., Kometer, M., Hasler, F. & Vollenweider, F. X. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J. Psychopharmacol 25, 1434–1452 (2011). · DOI · Paper page
  7. Rümmele, W. & Gnirss, F. Untersuchungen mit Psilocybin, einer psychotropen Substanz aus Psilocybe Mexicana. Schweiz Arch Neurol Neurochir Psychiatr 87, 365–385 (1961).
  8. Preller, K. H. & Vollenweider, F. X. In Behavioral Neurobiology of Hallucinogens, Entactogens, and Psychotomimetics Current Topics in Behavioral Neurosciences (eds Halberstadt, A. L., Nichols, D. E. & Vollenweider, F. X.) 360–389 (Springer, 2016).
  9. Austin, J. H. Zen and the Brain: Toward an Understanding of Meditation and Consciousness. (The MIT Press, 1998). · DOI · Paper page
  10. Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187, 268–283 (2006). · DOI · Paper page
  11. Piron, H. Meditation depth, mental health, and personal development. Journal for Meditation and Meditation Research 3, 45–58 (2003).
  12. Buchheld, N., Grossman, P. & Walach, H. Measuring mindfulness in insight meditation (Vipassana) and meditation-based psychotherapy: The development of the Freiburg Mindfulness Inventory (FMI). Journal for Meditation and Meditation Research 1, 11–34 (2001).
  13. Derogatis, L. SCL-90-R: Symptom Checklist-90-R: administration, scoring, and procedures manual. NCS Pearson (1996).
  14. Hood, R. W. Jr. The construction and preliminary validation of a measure of reported mystical experience. Journal for the scientific study of religion, 29–41 (1975). · DOI · Paper page
  15. Stace, W. (Philadelphia, Lippincott, 1960).

Cited by

See all 176

Metadata

Authors
Smigielski, L., Kometer, M., Scheidegger, M., Krähenmann, R., Huber, T., & Vollenweider, F. X.
Affiliations
University of Zurich (CH)
Corresponding author
Smigielski, Lukasz
Venue
Scientific Reports
Published
2019-10-24
Volume
9
Issue
1
Pages
14914-14914
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2981695213
Cited by
176
References
95
Citations by year
2026: 18 · 2025: 31 · 2024: 24 · 2023: 44 · 2022: 32 · 2021: 15 · 2020: 8 · 2019: 2
FWCI
16.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
Funders
Swiss Neuromatrix Foundation
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
  • Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords
psilocybin, mindfulness meditation, psychedelic therapy, dissolution of the self, self-transcendence, openness to experience, optimism, emotional reappraisal, emotion regulation, placebo response
MeSH terms
Attention, Buddhism, Emotions, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Social Behavior, Meditation, Mindfulness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. https://app.cochat.ai/papers/10.1038/s41598-019-50612-3
The paper
Smigielski, L., Kometer, M., Scheidegger, M., Krähenmann, R., Huber, T., & Vollenweider, F. X. (2019). Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Scientific Reports. https://doi.org/10.1038/s41598-019-50612-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.